Endpoint
Plasma glucagon-like peptide-1 (GLP-1)
A peptide of 36 or 37 amino acids that is derived from proglucagon and mainly produced by the intestinal L cells. Glp-1(1-37 or 1-36) is further N-terminally truncated resulting in glp-1(7-37) or glp-1-(7-36) which can be amidated. These glp-1 peptides are known to enhance glucose-dependent insulin release, suppress glucagon release and gastric emptying, lower blood glucose, and reduce food intake.
CAT:outcome/plasma-glp-1reported in pmol/L2 findings from 2 compounds
What moved it
How to read these marks2 findings · 2 compounds · 1 null · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| L-leucine | no effect | 1 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
| sodium chloride | up | 1 | Evidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited. |
Reported to move it
1 finding
sodium chloride — increases
LimitedEvidence strength: limited. Human evidence with several recorded weaknesses, or a design that tops out at limited.Finding“Arterial plasma concentrations of total GLP‐1 increased during glucose + NaCl and glucose alone, however, an apparent plateau (incremental AUC, lasting from 40–80 min) was significantly higher during glucose + NaCl compared with glucose alone.”
Quoted verbatim from Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP-1 but not GIP, CCK, and gastrin in plasma.. - Study
- crossover
- Dose
- 6 g (103 mmol) NaCl single oral dose dissolved with 75 g glucose in 500 mL tap water
- Population
- Healthy young men; 6 g oral NaCl added to a 75 g oral glucose load versus the glucose load alone, after a standardised 4-day sodium intake; arterial blood sampling
Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP-1 but not GIP, CCK, and gastrin in plasma.2020PMID:32770661Permalink
Measured, no effect detected
1 finding
L-leucine — no detected effect on
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“There was no clear effect of exercise or L-leucine supplementation on GLP-1, PYY, or ghrelin concentrations A, B, C, D, E, and F, respectively).”
Quoted verbatim from Acute L-Leucine Supplementation and Sprint Exercise Elicit Distinct Appetite and Inflammatory Responses in Persons with Overweight: A Randomized, Counterbalanced, and Crossover Design Study.. - Study
- crossover
- Dose
- 70 mg/kg body weight, three times daily (approximately 5 g/dose for a 70 kg adult)
- Population
- sedentary, overweight, healthy adult men
Acute L-Leucine Supplementation and Sprint Exercise Elicit Distinct Appetite and Inflammatory Responses in Persons with Overweight: A Randomized, Counterbalanced, and Crossover Design Study.2026PMID:41754131Permalink
How it is measured
Plasma glucagon-like peptide-1 by immunoassay from serial postprandial sampling after a fixed mixed-nutrient drink or during intraduodenal nutrient infusion. Whether the assay captured the total or the intact/active fraction is recorded with each finding; the two fractions are not interchangeable and differ by the rate of DPP-4 degradation.
Sources cited
2 papers
- Subject
- plasma glucagon-like peptide-1 (glp-1)
- Findings
- 2
- Papers
- 2
Acute L-Leucine Supplementation and Sprint Exercise Elicit Distinct Appetite and Inflammatory Responses in Persons with Overweight: A Randomized, Counterbalanced, and Crossover Design Study.record2026PMID:417541311 finding
Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP-1 but not GIP, CCK, and gastrin in plasma.record2020PMID:327706611 finding